COMPANY PROFILE

Epitopea

Explore full profile

Transatlantic cancer immunotherapeutics company

Montreal, CanadaFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Epitopea

Epitopea is a transatlantic cancer immunotherapeutics company with operations in Cambridge, UK, and Montreal, Canada, established in 2021. The company is focused on developing immunotherapies to treat cancer by targeting a novel class of tumor-specific antigens (TSAs) known as Cryptigen™ antigens.

These antigens are broadly shared among patients with the same type of cancer. Epitopea leverages a proprietary platform to identify these markers on the surface of cancer cells. The company is developing a pipeline of accessible, off-the-shelf RNA-based immunotherapies. This approach aims to provide broadly applicable cancer treatments.

Epitopea has entered into a license and research collaboration agreement with MSD (Merck) to identify Cryptigen™ tumor-specific antigens. The company has secured over $45 million in financing to support the strategic development and clinical entry of its lead product candidate, Cryptigen™.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Montreal, Canada
Employees: 50
Open positions: None listed
Dealroom signal: 87.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Biotech and Pharma, DT and LS, science-based
Technology: Hardware
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2024	$31M	$124M	Cambridge Innovation Capital · Invest Quebec · Fonds de solidarité FTQ · Jonathan Milner	↗
GRANT✓Other financing	Sep 2024	$658K	—	Undisclosed	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Epitopea website traffic

Latest recorded traffic for Epitopea is 3.2K monthly website visits, up 68.4% over the last three months. Epitopea's team grew 8.7% over the past year.

Latest monthly visits3.2K 3-month web change+68.4% 1-year team growth+8.7%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MTMitoRx TherapeuticsBiotechnology company developing novel therapeutics that reverse mitochondrial dysfunction	Exeter, United Kingdom	Operational	15	$13M	$29M
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational
CSCauseway SensorsProviding accurate real-time analysis at an accessible price	Belfast, United Kingdom	Operational
MIMironidSmall molecule therapeutics for hereditary kidney disease	Glasgow, United Kingdom	Operational
INInnovoTEXPharmaceutical solutions targeting solid tumors with TEX CORE platform for effective, well-tolerated cancer therapies	Austin, United States	Operational
ATAdoram TherapeuticsInnovative immunotherapies targeting solid tumors using allosteric biochemistry	Lancy, Switzerland	Operational